Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dinoprostone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 known ✓ | P35408 | 5/20 | 1.00 |
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER3 known ✓ | P43115 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 3/20 | 1.00 |
| ▸ | PTGIR | P43119 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGFR | P43088 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dinoprostone SCHEMBL24340817 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23909398 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23353214 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352922 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352614 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24223591 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24727254 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352819 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352791 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352988 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16790 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075710-A | Application of MIF gene silencing in preparation of medicine for treating premature rupture of membranes | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106210-A1 | METABOLITE BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSE OF BIOLOGICAL AGENTS IN ASTHMA | 재단법인 아산사회복지재단 | 2026-05-21 | — | — | WO | claimed |
| EP-4743097-A1 | THERAPEUTIC USE OF FIBROBLAST MODULATION OF MICROGLIA | FibroBiologics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4743098-A1 | THERAPEUTIC USE OF FIBROBLASTS FOR THE TREATMENT OF PSORIASIS | FibroBiologics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3729084-B1 | IMMUNE CELL ORGANOID CO-CULTURES | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-20 | — | — | EP | claimed |
| CN-121622700-B | Use of prostaglandin PGE1 or PGE2 for the preparation of a product promoting proliferation of depleted precursor T cells | 暨南大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122056990-A | Jinhuang powder external application ointment and application thereof in preparation of medicines for treating gonarthritis inflammatory synovitis | 李建 | 2026-05-19 | — | — | CN | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| US-20010051656-A1 | Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-12-13 | — | — | US | claimed |
| US-6266560-B1 | Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction | GENETRONICS, INC. | 2001-07-24 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999065563-A1 | ELECTRICALLY ASSISTED TRANSDERMAL METHOD AND APPARATUS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | GENETRONICS, INC. (US) | 1999-12-23 | — | — | WO | claimed |
| US-5919474-A | Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith | VIVUS, INC. (US) | 1999-07-06 | — | — | US | claimed |
| US-5820587-A | Method and kit for preventing erectile dysfunction | VIVUS INCORPORATED (US) | 1998-10-13 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0470251-B1 | LIQUID PROSTAGLANDIN COMPOSITION | GREEN CROSS CORP (JP) | 1996-02-07 | — | — | EP | claimed |